May 13, 2021 7:00 am EDT Cerecor Reports First Quarter 2021 Financial Results and Provides Business Updates
May 11, 2021 7:00 am EDT FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19
May 5, 2021 7:00 am EDT Cerecor Doses First Patient in a Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for the Treatment of Adult Onset Still’s Disease
Mar 29, 2021 7:00 am EDT Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002
Mar 2, 2021 7:00 am EST Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure and Mortality in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS
Feb 2, 2021 7:00 am EST Cerecor Announces Fast Track Designation for CERC-803 for the Treatment of Leukocyte Adhesion Deficiency Type II
Jan 20, 2021 7:00 am EST Cerecor Announces Proceeds from Option to Purchase Additional Shares of Common Stock Bringing Public Offering Proceeds to $40.7 Million
